Results 51 to 60 of about 530,239 (305)

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

06 | SUNTEL program: first experience of school integration of the ugly duckling sign with e-learning and peer education for melanoma awareness

Dermatology Reports
Background: Educational initiatives among young people are pivotal in promoting healthy behaviors, yet only a few studies to date have used peer education in schools to convey health messages for melanoma prevention.
Italian Melanoma Intergroup
doaj   +1 more source

Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis

Molecular Oncology, EarlyView.
This schematic outlines the workflow from biomarker identification to duplex MethyLight assay validation for epithelial ovarian cancer diagnosis using cfDNA‐based liquid biopsy. Initial screening of hypermethylated CpG candidates (cg02957270, cg10061138 cg00480298, COL2A1) was performed in tissue using ARMS‐PCR, COBRA, qPCR and image analysis. Selected
Deepa Bisht, Sameer Gupta, Amrita Chaurasia, Manisha Sachan   +3 more
wiley   +1 more source

Pharmacological Basis of Melanoma Chemotherapy [PDF]

, 2022
Melanoma is the most aggressive and lethal type of skin cancer. First-line therapy for metastatic melanoma is either immune checkpoint inhibitors or BRAF/MEK inhibitors, however, chemotherapy plays an important role in palliative treatment of refractory ...
Ito, Midori
core  

25 | A phase II, open-label study to improve compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas – the SONIBEC trial

Dermatology Reports
Background: Sonidegib is an effective treatment for laBCC, but it is associated with a risk of treatment-related adverse events (TRAEs), causing treatment discontinuation.
Italian Melanoma Intergroup
doaj   +1 more source

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies

OncoImmunology, 2023
Lymphocyte-activation gene-3 (LAG-3), an immune checkpoint receptor, negatively regulates T-cell function and facilitates immune escape of tumors. Dual inhibition of LAG-3 and programmed cell death receptor-1 (PD-1) significantly improved progression ...
Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen Adegoke, Alexander M. Menzies, Ines Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer   +9 more
doaj   +1 more source

Melanoma and Immunosuppression [PDF]

Dermatology, 2009
In a recent article, Richtig et al. [1] suggested that immunosuppression may be a risk factor for melanoma development and, in order to support this view, cited a study demonstrating an increased frequency of melanoma in organ transplant recipients receiving long-term immunosuppression [2] .
Belloni Fortina A, PIASERICO, STEFANO, Tonin E, ALAIBAC, MAURO SALVATORE ALESSANDRO, BELLONI FORTINA, ANNA   +4 more
openaire   +3 more sources

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Prospects for non-immunological molecular therapeutics in melanoma [PDF]

, 2010
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Tryfonopoulos, Dimitrios, Eustace, Alexander J., Mahgoub, Thamir, O\u27Donovan, Norma, Crown, John, O'Donovan, Norma   +5 more
core  

Melanoma-associated adhesion molecule MUC18/MCAM (CD146) and transcriptional regulator Mader in normal human CNS [PDF]

, 1998
The proteins MUC18 and Mader have been identified as markers of tumor progression in melanoma cells, MUC18, also known as MCAM (melanoma cell adhesion molecule) and as CD146 (endothelial antigen), is a cell adhesion molecule belonging to the ...
Müller, Norbert, Johnson, Judith P., Kirsch, Kathrin H., Hampel, Harald, Schwarz, Markus J., Ackenheil, Manfred, Penning, Randolph, Körschenhausen, Dirk   +7 more
core   +1 more source